DOW JONES23,231.33+577.47 2.55%
S&P 5002,721.48+62.07 2.33%
NASDAQ8,034.17+146.91 1.86%

BTIG Research Downgrades Cellular Biomedicine Gr to Neutral

BTIG Research analyst Amanda Murphy downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Buy to Neutral.

Benzinga · 03/05/2020 09:48

BTIG Research analyst Amanda Murphy downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Buy to Neutral.